Automate Your Wheel Strategy on KZIA
With Tiblio's Option Bot, you can configure your own wheel strategy including KZIA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KZIA
- Rev/Share 2.9311
- Book/Share -4.4782
- PB -2.4286
- Debt/Equity -0.037
- CurrentRatio 0.2063
- ROIC -9.4854
- MktCap 6255672.7296
- FreeCF/Share -8.7695
- PFCF -0.839
- PE -0.3989
- Debt/Assets 0.0079
- DivYield 0
- ROE 3.3537
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | KZIA | Maxim Group | -- | Buy | -- | $3 | Feb. 6, 2025 |
News
Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG
Published: October 01, 2025 by: PRNewsWire
Sentiment: Neutral
SYDNEY , Oct. 1, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage biotechnology company developing innovative therapies for brain cancers, today announced its participation in a fully funded Australian Medical Research Future Fund (MRFF) project titled "Sequential & Temporal Therapeutic Agility for the Treatment of Diffuse Midline Glioma (DMG)". Under this three-year initiative, a consortium of leading researchers will establish DMG-ADAPTS, an advanced AI-enabled clinical decision-making platform designed to optimize sequencing and timing of targeted therapies for diffuse midline glioma (DMG), including diffuse intrinsic pontine glioma (DIPG).
Read More
Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer
Published: June 05, 2025 by: PRNewsWire
Sentiment: Neutral
Trial is expected to provide key insights on how paxalisib therapy can be combined with established immunotherapies and standard of care chemotherapy to improve patient outcomes in advanced breast cancer SYDNEY , June 5, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing innovative therapies for difficult-to-treat cancers, today announced that the first patient has been dosed in a Phase 1b clinical trial sponsored by Kazia. The study evaluates paxalisib, the Company's dual PI3K/mTOR inhibitor, in combination with olaparib or pembrolizumab for patients with advanced breast cancer.
Read More
About Kazia Therapeutics Limited (KZIA)
- IPO Date 1999-01-06
- Website https://www.kaziatherapeutics.com
- Industry Biotechnology
- CEO John Edwin Friend II,
- Employees 9